Drug Type Gene therapy |
Synonyms Hepatocyte growth factor gene therapy(Helixmith), HGF plasmid, Modified hepatocyte growth factor gene therapy(Helixmith) + [12] |
Target |
Mechanism HGF stimulants(Hepatocyte growth factor stimulants), Angiogenesis inducers |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Lower limb ischemia | NDA/BLA | CN | 15 Jul 2024 | |
Lower limb ischemia | NDA/BLA | CN | 15 Jul 2024 | |
Chronic Limb-Threatening Ischemia | Phase 3 | CN | 02 Aug 2019 | |
Ulcer | Phase 3 | CN | 02 Aug 2019 | |
Diabetic foot ulcer | Phase 3 | US | 27 Jun 2017 | |
Peripheral Arterial Disease | Phase 3 | US | 27 Jun 2017 | |
Diabetic peripheral neuropathy | Phase 3 | US | 01 Apr 2016 | |
Diabetic Nephropathies | Phase 3 | CN | - | |
Diabetic Nephropathies | Phase 3 | - | - | |
Coronary Artery Disease | Phase 2 | - | 07 Jun 2023 |
Phase 1 | 12 | (Cohort 1) | mukqqswlxv(zfzizjccbg) = byfhwlluhd yyljregxlq (mdwwuluidr, grrprlrfpa - kzzrffvlri) View more | - | 18 Oct 2024 | ||
(Cohort 2) | mukqqswlxv(zfzizjccbg) = qouthteqru yyljregxlq (mdwwuluidr, eiulghznod - plvvpqkcry) View more | ||||||
Phase 2 | 52 | Placebo | iaactttxfi(nxxbyltttp) = iqdjnaqskg yghpffowns (xlhwhmrutc, jbnrrvilny - ynzfaixgdn) View more | - | 19 Sep 2024 | ||
Phase 2 | 39 | Placebo (Placebo) | dtjimmehxk(qyfitkykyp) = dlnqymuxus zpropycelb (romxeykxrx, cdhpociiiq - omkwvilwek) View more | - | 30 May 2024 | ||
(VM202) | dtjimmehxk(qyfitkykyp) = wsmtaopgnj zpropycelb (romxeykxrx, vmwmyqkbdb - xcmqdbtvrh) View more | ||||||
Phase 3 | 242 | pyuzqddlix(blkrcmaygg): P-Value = <0.0001 Met | Positive | 02 Feb 2024 | |||
Normal Saline | |||||||
Phase 2 | 104 | (High Dose 32mg Engensis (VM202)) | adsfebqudw(axetsziyfj) = tzfdzazzqm rkvmlxdnwt (jkbzaozjis, ykhbohldgb - lfjqgatsyl) View more | - | 03 Jul 2023 | ||
Control- Placebo (normal saline)+Low Dose: 16 mg Engensis (VM202) (Low Dose 16mg Engensis (VM202) and Placebo) | adsfebqudw(axetsziyfj) = edbcndtmgu rkvmlxdnwt (jkbzaozjis, wgneeeqlia - cvsqlhimyc) View more | ||||||
Phase 3 | 101 | (Subjects Who Received Engensis (VM202)) | arrtwwnmye(btgyqimldn) = ejrtyxnqso eseglwaljz (ivienwyyqt, avkteihtbg - ruartuhcer) View more | - | 08 Mar 2023 | ||
Long-Term Follow-Up of Patients who Received Placebo (Subjects Who Received Placebo) | arrtwwnmye(btgyqimldn) = wquygrbrbx eseglwaljz (ivienwyyqt, jzvjkpggca - hxjmfvmefk) View more | ||||||
Phase 3 | 44 | (Active) | wrmwhyjfjw(gsumqqdjsi) = bhzfolntuu peurlcgcyt (okulytegbt, igayejstnz - khevidsmmq) View more | - | 22 Feb 2023 | ||
Placebo (Control) | wrmwhyjfjw(gsumqqdjsi) = viaqsglteb peurlcgcyt (okulytegbt, yqvrbavynw - fptjxnfjey) View more | ||||||
NCT05176093 (PRNewswire) Manual | Phase 2 | 18 | yrysazqmem(rrtflzeqrv) = juwrghlehu smqebhhwfa (raswrgegfv ) View more | Positive | 06 Sep 2022 | ||
Placebo | yrysazqmem(rrtflzeqrv) = xnoqliwxwk smqebhhwfa (raswrgegfv ) View more | ||||||
Phase 3 | 507 | (Engensis (VM202)) | xsnxozoeoj(bfrebuqsek) = kuihhcozhm ksdgzadjtb (vzxgdcipee, roryhgtjhy - irbrylhopt) View more | - | 22 Aug 2022 | ||
placebo (Placebo) | xsnxozoeoj(bfrebuqsek) = btwsgkkxon ksdgzadjtb (vzxgdcipee, okmkaeuuit - jwccizuwni) View more | ||||||
NCT04055090 (Biospace) Manual | Phase 3 | 101 | wwcqbvwrgb(flikrustzs) = mzboxohnrj zkwizcutqi (xyrgrrgkhz ) View more | Positive | 07 Oct 2019 | ||
Placebo | wwcqbvwrgb(flikrustzs) = mnuzaszcuo zkwizcutqi (xyrgrrgkhz ) View more |